CytoSeek is developing its Artificial Membrane Binding Protein (AMBP) technology to enhance cell therapies for use in tumour therapies. AMBPs, which bind to virtually all cell types, have a modular design that allows rapid prototyping to deliver new functionalities. Currently, we are developing AMBPs that can provide homing, immunomodulation, and/or hypoxia resistance functionality.